三甲散加减联合西医常规治疗急性冠脉综合征临床研究

目的:观察三甲散加减联合西医常规治疗急性冠脉综合征(ACS)的疗效及对炎症因子影响。方法:将93例ACS患者随机分为2组。对照组给予抗凝、抗血小板聚集、抗心肌缺血等常规治疗;治疗组在对照组治疗基础上加用三甲散为基础方加减治疗。疗程2周,比较治疗前后2组疗效及观察血清超敏C-反应蛋白(hs-CRP)、基质金属蛋白酶9(MMP-9)的含量变化。结果:治疗组总有效率为87.5%,优于对照组的64.4%,差异有显著性意义(P0.05)。2组治疗后hs-CR P、MMP-9均较治疗前降低(P0.05),治疗组较对照组降低更明显,差异有显著性意义(P0.05)。结论:三甲散加减联合西医常规治疗能有效抑制炎症因子,其可能为治疗ACS的机制所在。

Clinical Observation of Modified Sanjia Powder Combined with Conventional Western Medicine for Treatment of Acute Coronary Syndrome

Objective： To observe the therapeutic effect of modified Sanjia powder combined with conventional western medicine for treatment of acute coronary syndrome（ACS）, and to explore its effect on inflammatory factors. Methods： Ninety-three ACS patients were randomly divided into two groups. The control group was given conventional anticoagulant, anti-platelet aggregation, anti-myocardial ischemia treatment. Based on the treatment for the control group, the treatment group was given oral use of modified Sanjia powder. The treatment course in both groups lasted 2 weeks. After treatment the therapeutic effect was evaluated, and the changes of the serum contents of high-sensitivity C reactive protein（hs-CRP）and matrix metalloproteinase 9（MMP-9） were observed. Results： The total effective rate was 87.5% in the treatment group, and was superior to 64.4% in the control group, the difference being statistically significant （P 〈 0.05）. The serum contents of hs-CRP and MMP-9 were decreased in the two groups after treatment （P 〈 0.05 compared with those before treatment）. Conclusion： The therapeutic mechanism of modified Sanjia powder combined with conventional western medicine for ACS probably is related with the inhibition of inflammatory factors.